Name: ANAVEX LIFE SCIENCES CORP (AVXL) Stock
Brand: ANAVEX LIFE SCIENCES CORP
Rating: 5.5 (3 reviews)

AVXL Latest News, Press Relases and Analysis

All

Press Releases

a day ago - By: Benzinga

Anavex Life Sciences' Alzheimer's Drug Candidate Shows Continued Long-Term Benefit Versus Control Group

a day ago - By: Anavex Life Sciences Corp.

Anavex Life Sciences Announces Continued Long-Term Benefit from Oral Blarcamesine Compared to Decline Observed in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) Control Group

9 days ago - By: Stocktwits

Anavex Life Sciences Stock Sparks Retail Banter On Hopes Of EMA Conditional Nod For Alzheimer's Drug, Big Pharma Tie-Up

20 days ago - By: Anavex Life Sciences Corp.

Anavex Life Sciences Announces Presentation at the 35th Alzheimer Europe Conference ‘Connecting Science and Communities: The Future of Dementia Care’

a month ago - By: Stocktwits - Mentions: EAOR ITOT

Anavex Life Sciences Stock Just Shot Up 7% Today – Here’s An Important Update

a month ago - By: Anavex Life Sciences Corp.

Anavex Life Sciences Announces Successful Development of Once-Daily Oral Tablet Formulation for the ANAVEX®3-71 Program

a month ago - By: Anavex Life Sciences Corp.

Anavex Life Sciences Announces Positive Topline Results from Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia

a month ago - By: Anavex Life Sciences Corp.

Anavex Life Sciences Announces Publication of Oral Blarcamesine Describing a New Class of Clinical Precision Medicine from Phase IIb/III Alzheimer’s Disease Trial

2 months ago - By: Stocktwits - Mentions: EAOR VTWG

Anavex Life Sciences Stock Rises After Experimental Alzheimer’s Drug Slows Cognitive Decline In Study

2 months ago - By: Anavex Life Sciences Corp.

Anavex Life Sciences Announces Oral Blarcamesine Cognitive Resilience Results Approximating Normal Aging in New Precision Medicine Clinical Data from Phase IIb/III Alzheimer’s Disease Trial

3 months ago - By: Benzinga

What to Expect from Anavex Life Sciences's Earnings

2 months ago - By: Anavex Life Sciences Corp.

Anavex Life Sciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference 2025

2 months ago - By: Anavex Life Sciences Corp.

Anavex Life Sciences Reports New Publication in Medical Journal Highlighting the Established Precise Autophagy Mechanism with Blarcamesine

2 months ago - By: Anavex Life Sciences Corp.

Anavex Life Sciences Announces New Publication in Medical Journal: Blarcamesine Prevented Cognitive Impairment in Animal Model of Alzheimer’s Disease

3 months ago - By: Anavex Life Sciences Corp.

Anavex Life Sciences Reports Fiscal 2025 Third Quarter Financial Results and Provides Business Update

4 months ago - By: Stocktwits

Anavex Life Sciences Stock Falls After Hours On $300M Raise Plan; Retail Traders Think It’s A ‘Smart’ Move

3 months ago - By: Anavex Life Sciences Corp.

Anavex Life Sciences to Announce Fiscal 2025 Third Quarter Financial Results on Tuesday, August 12, 2025

3 months ago - By: Anavex Life Sciences Corp.

Anavex Life Sciences Announces Positive Precision Medicine Results from up to 4-Years of Oral Blarcamesine Treatment in Phase IIb/III Open-Label Extension Trial in Early Alzheimer’s Disease

4 months ago - By: Stocktwits - Mentions: BULL SBET BBAI OSCR

Top 5 Trending Stocks On Stocktwits Today: Webull, SharpLink, Anavex Life Sciences, BigBear.ai, And Oscar Health

6 months ago - By: Anavex Life Sciences Corp.

Anavex Life Sciences to Participate at Upcoming Healthcare Conferences

6 months ago - By: Anavex Life Sciences Corp.

Anavex Life Sciences Reports Fiscal 2025 Second Quarter Financial Results and Provides Business Update

6 months ago - By: Anavex Life Sciences Corp.

Anavex Life Sciences to Announce Fiscal 2025 Second Quarter Financial Results on Tuesday, May 13, 2025

6 months ago - By: Anavex Life Sciences Corp.

ANAVEX LIFE SCIENCES CORP (AVXL) Stock News

AVXL Latest News, Press Relases and Analysis

Anavex Life Sciences' Alzheimer's Drug Candidate Shows Continued Long-Term Benefit Versus Control Group

Anavex Life Sciences Announces Continued Long-Term Benefit from Oral Blarcamesine Compared to Decline Observed in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) Control Group

Anavex Life Sciences Stock Sparks Retail Banter On Hopes Of EMA Conditional Nod For Alzheimer's Drug, Big Pharma Tie-Up

Anavex Life Sciences Announces Presentation at the 35th Alzheimer Europe Conference ‘Connecting Science and Communities: The Future of Dementia Care’

Anavex Life Sciences Stock Just Shot Up 7% Today – Here’s An Important Update

Anavex Life Sciences Announces Successful Development of Once-Daily Oral Tablet Formulation for the ANAVEX®3-71 Program

Anavex Life Sciences Announces Positive Topline Results from Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia

Anavex Life Sciences Announces Publication of Oral Blarcamesine Describing a New Class of Clinical Precision Medicine from Phase IIb/III Alzheimer’s Disease Trial

Anavex Life Sciences Stock Rises After Experimental Alzheimer’s Drug Slows Cognitive Decline In Study

Anavex Life Sciences Announces Oral Blarcamesine Cognitive Resilience Results Approximating Normal Aging in New Precision Medicine Clinical Data from Phase IIb/III Alzheimer’s Disease Trial

What to Expect from Anavex Life Sciences's Earnings

Anavex Life Sciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference 2025

Anavex Life Sciences Reports New Publication in Medical Journal Highlighting the Established Precise Autophagy Mechanism with Blarcamesine

Anavex Life Sciences Announces New Publication in Medical Journal: Blarcamesine Prevented Cognitive Impairment in Animal Model of Alzheimer’s Disease

Anavex Life Sciences Reports Fiscal 2025 Third Quarter Financial Results and Provides Business Update

Anavex Life Sciences Stock Falls After Hours On $300M Raise Plan; Retail Traders Think It’s A ‘Smart’ Move

Anavex Life Sciences to Announce Fiscal 2025 Third Quarter Financial Results on Tuesday, August 12, 2025

Anavex Life Sciences Announces Positive Precision Medicine Results from up to 4-Years of Oral Blarcamesine Treatment in Phase IIb/III Open-Label Extension Trial in Early Alzheimer’s Disease

Top 5 Trending Stocks On Stocktwits Today: Webull, SharpLink, Anavex Life Sciences, BigBear.ai, And Oscar Health

Anavex Life Sciences to Participate at Upcoming Healthcare Conferences

Anavex Life Sciences Reports Fiscal 2025 Second Quarter Financial Results and Provides Business Update

Anavex Life Sciences to Announce Fiscal 2025 Second Quarter Financial Results on Tuesday, May 13, 2025

Anavex Life Sciences Announces Full Enrollment of Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia